INTRODUCTION
============

Misfolded proteins are toxic to cells and are believed to cause or contribute to many human diseases, including most neurodegenerative diseases ([@B13]). Accordingly, cells have developed stress responses to identify and destroy misfolded proteins. Two important such pathways are the unfolded protein response (UPR) and the Rpn4 response ([@B38]; [@B35]). The UPR senses misfolded proteins within the endoplasmic reticulum (ER) and responds in a complex manner to mitigate this threat. Central to this response is the activation of the transcription factor Hac1, which mediates a broad transcriptional program to remodel the cell and allow it to better address the proteotoxic threat ([@B33]). This includes transcription of ER chaperones to promote protein folding, as well as the machinery involved in ER-associated degradation (ERAD) to destroy those proteins that cannot be refolded. The UPR is also capable of down-regulating protein synthesis and, in higher organisms, initiating apoptosis, the latter pathway likely reserved for the most severe cases of proteotoxic stress ([@B17]; [@B35]). Of interest, for reasons that are not entirely clear, the UPR also stimulates the synthesis of phospholipids ([@B2])

The transcription factor Rpn4 mediates a second proteotoxic stress response that is believed to monitor the functional capacity of the proteasome---the large multisubunit protease that is responsible for most selective protein degradation in eukaryotes ([@B38]). Rpn4 recognizes a consensus motif in the promoters of all known proteasome subunits ([@B20]), allowing Rpn4 to orchestrate new proteasome synthesis in a concerted stoichiometric manner. However, Rpn4 is also a substrate of the proteasome with an extremely short half-life ([@B38]). Under conditions that compromise or overwhelm proteasome function, Rpn4 is stabilized. This results in new proteasome synthesis, increasing degradative capacity and eventually restoring rapid degradation of Rpn4, which normalizes the stress response. This pathway appears to be functionally conserved in higher organisms, where it is mediated by the transcription factor Nrf1 ([@B23]; [@B31]).

The lipid droplet is an organelle-like structure that houses large quantities of neutral lipids (mainly triacylglycerols and sterol esters) and is bounded by a phospholipid monolayer ([@B24]; [@B36]). One function of the lipid droplet is believed to be in metabolism---storing and releasing these neutral lipids as needed to meet the cell\'s energy requirements ([@B24]). However, the lipid droplet remains poorly understood. It has become apparent that the lipid droplet has its own dedicated and complex proteome ([@B1]). In addition, lipid droplets appear to be dynamic, capable of changing in size and number under different cellular conditions ([@B4], [@B5]). Here we identify the lipid droplet phospholipase Lpl1 as a component of the Rpn4 proteotoxic stress response. Loss of Lpl1 results in multiple proteolytic defects, including synthetic genetic interactions with members of the unfolded protein response. These defects are accompanied by alterations in lipid droplet homeostasis. These results suggest an important role for the lipid droplet in proteotoxic stress responses and provide a direct mechanistic link between these seemingly unrelated pathways.

RESULTS
=======

Lpl1 is a target of the Rpn4 proteotoxic stress response
--------------------------------------------------------

We recently carried out a proteomic analysis of the cellular response to trivalent arsenic in the yeast *Saccharomyces cerevisiae* ([@B9]). Under these conditions, Rpn4 protein levels are increased by ∼20-fold, and this results in a corresponding increase in the abundance of proteasome subunits. Among the nearly 4600 proteins for which data were available, we noticed that the protein Lpl1 was strongly induced by arsenic in a manner that was similar to some Rpn4 targets ([Figure 1A](#F1){ref-type="fig"}). Rpn4 recognizes its targets through a consensus motif in their promoters known as the proteasome-associated control element (PACE; [@B20]). We identified a canonical PACE motif within the *LPL1* promoter that was identical to that of established Rpn4 targets such as Rpn5 and Beta5 (Pre2; [Figure 1B](#F1){ref-type="fig"}). Furthermore, Lpl1\'s PACE motif was situated within the first 200 nucleotides preceding the start codon, which is the typical location ([@B19]). To test directly whether *LPL1* was a transcriptional target of Rpn4, we performed reverse-transcription PCR (RT-PCR) under the same conditions as in [Figure 1A](#F1){ref-type="fig"}. *LPL1* was strongly induced at the RNA level, and this induction was largely dependent on Rpn4 ([Figure 1C](#F1){ref-type="fig"}). Thus Lpl1 is a target of the Rpn4 proteotoxic stress response.

![Lpl1 is regulated by Rpn4. (A) Relative protein abundance of Lpl1 at 0, 1, and 4 h after treatment with sodium arsenite (1 mM). Data were generated using a tandem mass tag-based mass spectrometry approach ([@B9]). Act1, a control protein, showed no change. Error bars represent SDs from triplicate cultures. In addition, differences between untreated and treated samples were statistically significant by Student\'s *t* test (*p* \< 0.01) for Lpl1 but not Act1. (B) Schematic diagram of the *LPL1* gene with its associated 5′-untranslated region. A classical PACE motif is present, with its location indicated relative to the start codon. This PACE motif is identical to that of other well-established Rpn4 targets, such as Rpn5 and Beta5 (Pre2). (C) Stress-inducible transcription of *LPL1* in wild-type and *rpn4Δ* cells, as determined by RT-PCR. Treatment was with sodium arsenite (1 mM) for 1 h. *ACT1* (bottom) serves as a control. (D) Schematic of a generic phospholipid with the cleavage sites indicated for type B phospholipases such as Lpl1. R~1~ and R~2~, fatty acyl groups; R~3~, polar head group (e.g., choline, ethanolamine, serine, inositol).](716fig1){#F1}

Whereas most known targets of Rpn4 are proteasome subunits or proteasome-interacting proteins, Lpl1 is a component of the lipid droplet ([@B27]). By sequence and functional analysis, it is a type B phospholipase, allowing it to cleave phospholipids at the sn-1 and sn-2 positions, releasing free fatty acids from the three-carbon backbone, which retains its polar head group ([Figure 1D](#F1){ref-type="fig"}; [@B27]). Lpl1 showed a relatively broad substrate specificity in vitro, acting on major species such as phosphatidylethanolamine, phosphatidylcholine, and phosphatidylserine, although it showed much lower activity against phosphatidylinositol ([@B27]).

Functional relationship between Lpl1 and the unfolded protein response
----------------------------------------------------------------------

Control of Lpl1 by Rpn4 suggested a potential role for Lpl1 in protein degradation. We examined the *lpl1Δ* mutant for growth defects after exposure to various proteotoxic stresses but were unable to identify a phenotype (unpublished data). However, when *LPL1* was deleted in a *hac1Δ* background, we observed robust phenotypes in response to multiple causes of proteotoxic stress, including elevated temperature and the abnormal amino acid canavanine, which is incorporated into nascent proteins, causing them to misfold ([Figure 2A](#F2){ref-type="fig"}). Hac1 is a transcription factor and a master regulator of the UPR, which is distinct from the Rpn4 response. The UPR responds specifically to misfolded proteins within the ER, and Hac1 orchestrates a complex transcriptional response to mitigate this threat ([@B33]; [@B37]). The *hac1Δlpl1Δ* phenotype could be complemented by restoration of plasmid-derived *LPL1*, confirming that the phenotype was indeed caused by loss of Lpl1 ([Figure 2B](#F2){ref-type="fig"}). One potential explanation for such a synthetic phenotype is that the UPR is constitutively induced in the *lpl1Δ* mutant, compensating for defects in this mutant. Hac1 is activated by splicing of its mRNA ([@B37]). We saw no evidence of increased *HAC1* splicing in the *lpl1Δ* mutant by RT-PCR ([Figure 2C](#F2){ref-type="fig"}). Similarly, the classical UPR target Kar2 (the yeast orthologue of BiP) was not up-regulated at the protein level in the *lpl1Δ* mutant ([Figure 2D](#F2){ref-type="fig"}), although its levels were slightly decreased in the absence of Hac1, as expected ([Figure 2E](#F2){ref-type="fig"}).

![Proteotoxic phenotypes of the *hac1Δlpl1Δ* mutant. (A) Growth of wild-type, *lpl1Δ*, *hac1Δ*, and *hac1Δlpl1Δ* strains in the presence of canavanine (1.5 µg/ml) or at elevated temperature, as indicated. Cells were spotted in threefold serial dilutions and cultured for 2--4 d. (B) Growth of wild-type, *lpl1Δ*, *hac1Δ*, and *hac1Δlpl1Δ* strains expressing an empty vector and *hac1Δlpl1Δ* expressing *LPL1* in the presence or absence of canavanine (1.5 µg/ml), as indicated. Cells were spotted in threefold serial dilutions and cultured for 2--4 d at 30°C. (C) Splicing of *HAC1*, as determined by RT-PCR, in wild-type and *lpl1Δ* strains. A wild-type strain treated with tunicamycin (5 µg/ml), an inducer of the unfolded protein response, serves as a positive control. *ACT1* (bottom) serves as a control. (D) Kar2 protein levels in whole-cell extracts of wild-type and *lpl1Δ* strains, as determined by SDS--PAGE followed by immunoblot with anti-Kar2 antibody (top) or anti-Pgk1 antibody (bottom; loading control). (E) Kar2 protein levels in wild-type, *lpl1Δ*, *hac1Δ*, and *hac1Δlpl1Δ* strains. Exponential-phase cells cultured in synthetic medium were treated at 37°C for 1 h. Whole-cell extracts were prepared and analyzed by SDS--PAGE followed by immunoblot with anti-Kar2 antibody (top) or anti-Pgk1 antibody (bottom; loading control).](716fig2){#F2}

Lpl1 functions in protein degradation
-------------------------------------

The preceding regulatory and phenotypic data suggest a role for Lpl1 in proteasome-mediated protein degradation. Because proteasomes preferentially destroy ubiquitinated proteins, defects in the pathway may lead to an accumulation of high--molecular weight ubiquitin immunoreactive material. Indeed, we observed an accumulation of these ubiquitinated species in the *hac1Δlpl1Δ* mutant, consistent with a significant protein degradation defect ([Figure 3A](#F3){ref-type="fig"}). We next examined a specific protein, CPY\*, which is a classical substrate of the ERAD pathway. Wild-type and *lpl1Δ* cells showed similarly rapid degradation of this substrate, with a half-life of \<20 min ([Figure 3B](#F3){ref-type="fig"}). CPY\* degradation was attenuated in the *hac1Δ* mutant, as expected. Turnover of CPY\*, however, was much more strongly attenuated in the *hac1Δlpl1Δ* mutant, which was reflected not only in the rate of turnover, but also in the elevation of steady-state CPY\* levels ([Figure 3B](#F3){ref-type="fig"}). This elevation of steady-state protein levels reflects the fact that in a cycloheximide chase assay, where there is no pulse period, the zero time point represents steady-state protein abundance. Thus steady-state levels may increase if there is a strong enough degradative defect or even decrease if there is a strong degradative advantage ([@B11]; [@B10]; [@B29]). To determine whether this effect was specific to ERAD substrates, we looked at a model cytoplasmic substrate of the proteasome, Δ2-GFP ([@B18]), under similar conditions. This substrate also showed a high rate of degradation, but we did not detect any stabilization in the *lpl1Δ*, *hac1Δ*, or *hac1Δlpl1Δ* mutant ([Figure 3C](#F3){ref-type="fig"}).

![Protein degradation defects in the *hac1Δlpl1Δ* mutant. (A) Levels of ubiquitin conjugates in whole-cell extracts of wild-type, *lpl1Δ*, *hac1Δ*, and *hac1Δlpl1Δ* strains, as determined by SDS--PAGE followed by immunoblot with anti-ubiquitin antibody (top) or anti-Pgk1 antibody (bottom; loading control). Experiment was performed at 37°C. (B) Cycloheximide chase analysis of CPY\* turnover in wild-type, *lpl1Δ*, *hac1Δ*, and *hac1Δlpl1Δ* strains, as determined by SDS--PAGE followed by immunoblot with anti-HA antibody (top) or anti-actin antibody (bottom; loading control). Experiment was performed at 37°C. See Supplemental Figure S1 for quantitation. (C) Cycloheximide chase analysis of turnover of the cytoplasmic proteasome substrate Δ2-GFP, as determined by SDS--PAGE followed by immunoblot with anti-HA antibody (top) or anti-Pgk1 antibody (bottom; loading control). Experiment was performed at 37°C. (D) Growth of wild-type, *lpl1Δ*, *hac1Δ*, and *hac1Δlpl1Δ* strains expressing galactose-inducible wild-type *STE6* or the misfolded mutant *ste6-Q1249X.* Cells were spotted in threefold serial dilutions and cultured for 4 d at 35°C. (E) Levels of phosphorylated eIF2α (Ser-51) in whole-cell extracts of wild-type, *lpl1Δ*, *hac1Δ*, and *hac1Δlpl1Δ* strains treated with sodium arsenite (0.2 mM), as determined by SDS--PAGE followed by immunoblot with anti--phospho-eIF2α antibody (top) or anti-Pgk1 antibody (bottom; loading control). Experiment was performed at 37°C.](716fig3){#F3}

Multiple classes of ERAD substrates have been identified, including ER lumenal substrates (such as CPY\*) and ER membrane substrates. The 12-transmembrane-domain protein Ste6 is a classical and robust ERAD substrate. In wild-type cells, expression of mutant Ste6 does not produce a growth defect, as these cells can rapidly destroy misfolded Ste6 ([@B21]). However, mutants defective in Ste6 degradation show growth defects that reflect the underlying toxicity of this misfolded protein. We expressed mutant *ste6-Q1249X* in these strains, along with wild-type Ste6 as a control. Wild-type and *lpl1Δ* cells showed no defect ([Figure 3D](#F3){ref-type="fig"}). By contrast, the *hac1Δ* mutant showed a growth defect, consistent with a defect in Ste6 degradation. Again, this defect was dramatically exacerbated in the *hac1Δlpl1Δ* double mutant ([Figure 3D](#F3){ref-type="fig"}). One useful aspect of this assay is that it integrates specific degradation defects with an in vivo readout of physiological relevance.

A hallmark of many proteotoxic stressors is the phosphorylation of the translation initiation factor eIF2α at serine-51, a pathway referred to as the integrated stress response ([@B17]). This phosphorylation inhibits eIF2 function, thereby limiting protein synthesis by the ribosome. Under conditions in which protein misfolding is prevalent, reducing the synthesis of new proteins may be advantageous. The UPR, for example, has long been known to promote eIF2α phosphorylation ([@B17]). We recently showed that trivalent arsenic is a potent inducer of eIF2α phosphorylation in yeast ([@B9]), although the underlying mechanism is unknown. We monitored eIF2α phosphorylation in these strains after arsenic treatment. The *hac1Δlpl1Δ* mutant showed increased levels of eIF2α phosphorylation ([Figure 3E](#F3){ref-type="fig"}), compatible with an underlying defect in proteotoxic stress response in this mutant. Taken together, these data suggest an important role for Lpl1 in quality control protein degradation by the proteasome.

Relationship between Lpl1 and phospholipid metabolism
-----------------------------------------------------

To obtain a better understanding of the role of Lpl1 in protein degradation, we sought to understand the basis for the relationship between Lpl1 and Hac1. According to microarray and other analyses, the UPR and Hac1 have potentially hundreds of transcriptional targets ([@B33]). These targets fall into a smaller number of categories, including ER chaperones, dedicated ERAD components, secretory pathway genes, phospholipid metabolism genes, and others ([Figure 4A](#F4){ref-type="fig"}). Control of phospholipid synthesis by the UPR has been recognized for almost 20 years ([@B3]; [@B17]), although its precise role in counteracting proteotoxic stress has remained somewhat unclear. Naturally, this aspect of the UPR was intriguing, given that Lpl1 also functions in phospholipid metabolism. The Hac1 target Cho2 promotes synthesis of phosphatidylcholine, an abundant membrane phospholipid, from phosphatidylethanolamine. We constructed a *cho2Δlpl1Δ* double mutant and tested its ability to survive various proteotoxic stressors. The *cho2Δlpl1Δ* mutant showed strong sensitivities to canavanine, phenocopying the *hac1Δlpl1Δ* mutant ([Figure 4B](#F4){ref-type="fig"}). We also detected a strong growth defect of *cho2Δlpl1Δ* on cadmium chloride, a divalent heavy metal and another well-established cause of proteotoxicity ([@B28]). To gauge the specificity of this interaction, we looked at Dga1, which is also involved in lipid metabolism but functions in the unrelated triacylglycerol synthesis pathway and is not a known target of the UPR. In contrast, a *dga1Δlpl1Δ* mutant showed no effect under these conditions ([Figure 4B](#F4){ref-type="fig"}). It is worth noting that the *cho2Δ* mutant alone showed sensitivity under these conditions, suggesting some degree of proteotoxic stress defect on its own ([Figure 4B](#F4){ref-type="fig"}; see also [@B32]).

![Proteotoxic phenotypes of *cho2Δlpl1Δ* and *psd1Δlpl1Δ* mutants. (A) Major classes of transcriptional targets for Hac1. (B) Growth of wild-type, *lpl1Δ*, *cho2Δ*, *cho2Δlpl1Δ*, *dga1Δ*, and *dga1Δlpl1Δ* strains in the presence of cadmium chloride (30 µM) or canavanine (1.5 µg/ml), as indicated. Cells were spotted in threefold serial dilutions and cultured at 30°C for 2--9 d. (C) Growth of wild-type, *lpl1Δ*, *psd1Δ*, and *psd1Δlpl1Δ* strains in the presence or absence of canavanine (1.5 µg/ml), as indicated. Cells were spotted in threefold serial dilutions and cultured at 30°C for 2--4 d.](716fig4){#F4}

Psd1 functions upstream of Cho2, promoting conversion of phosphatidylserine to phosphatidylethanolamine. We tested a *psd1Δlpl1Δ* mutant, which also showed a growth defect when treated with canavanine ([Figure 4C](#F4){ref-type="fig"}), although the severity of the pheno­type was less than that of *cho2Δlpl1Δ*. We did not detect synthetic genetic effects when *lpl1Δ* was combined with other mutants of the UPR such as Hrd1, a core component of the ERAD pathway, or Ino1, which mediates phosphatidylinositol synthesis via a metabolic pathway distinct from that which synthesizes phos­phatidylserine, phosphatidylethanolamine, and phosphatidylcholine (unpublished data).

Modulation of lipid droplet dynamics by Lpl1
--------------------------------------------

Lipid droplets are small, organelle-like structures in which a phospholipid monolayer surrounds a core of mostly neutral lipids, principally triacylglycerols and sterol esters. They can be visualized using fluorescence microscopy ([@B32]; [@B27]). In wild-type cells under normal conditions, there are typically 5--10 distinct lipid droplets per cell, and these are small and uniform in size. *cho2Δ* cells show extremely large lipid droplets, which can be up to 50 times the volume of wild-type lipid droplets ([@B5]). These cells also have many fewer lipid droplets and, in many cases, only a single dominant lipid droplet.

We confirmed the finding of supersized lipid droplets in *cho2Δ* cells ([Figure 5A](#F5){ref-type="fig"}), which frequently showed a single massive lipid droplet, with few or no accompanying smaller lipid droplets. This type of lipid droplet was virtually never seen in wild-type cells. The *lpl1Δ* mutant appeared similar to wild type. However, loss of Lpl1 in the *cho2Δ* background markedly altered the lipid droplet profile ([Figure 5, A and B](#F5){ref-type="fig"}). The number of cells with a single dominant lipid droplet was reduced. In their place were cells with lipid droplets that were greater in number but smaller in size than the supersized lipid droplets of *cho2Δ* ([Figure 5, A and B](#F5){ref-type="fig"}). Because these lipid droplets were still larger than those seen in wild-type cells, we referred to this pattern as "intermediate." It is worth noting that such intermediate-type cells can be seen in the *cho2Δ* mutant (see also [@B5]), but their abundance is significantly increased upon loss of Lpl1. These findings indicate that Lpl1 functions in the dynamic regulation of lipid droplets. Furthermore, the partial restoration of the *cho2Δ* phenotype suggests that Lpl1 may be required for the formation of supersized lipid droplets in the *cho2Δ* mutant.

![Lpl1 affects lipid droplet dynamics. (A) Representative images of lipid droplets, as visualized by fluorescence microscopy for the indicated strains. *cho2Δ* cells show a relative accumulation of cells with a single very large ("supersized") lipid droplet. *cho2Δlpl1Δ* cells show a relative accumulation of cells with an intermediate phenotype (i.e., lipid droplets that are smaller but more numerous than those seen in *cho2Δ*). (B) Quantitation of normal, intermediate, and supersized lipid droplets. Six hundred cells were counted (in 100 cell groups) for each strain. Error bars represent SDs. Asterisk, statistically significant by Student\'s *t* test (*p* \< 0.001).](716fig5){#F5}

Relationship between Rpn4 and phospholipid metabolism
-----------------------------------------------------

Stress-inducible expression of Lpl1 is dependent on Rpn4 ([Figure 1, B and C](#F1){ref-type="fig"}). Thus the preceding data on Lpl1 suggest a potential relationship between phospholipid metabolism and the Rpn4 proteotoxic stress response, a possibility that has not been previously considered. We therefore examined the consequences of compromising phospholipid metabolism in the *rpn4Δ* mutant. First, we found that the *rpn4Δ cho2Δ* mutant showed a strong growth defect when protein misfolding was broadly induced by canavanine ([Figure 6A](#F6){ref-type="fig"}). Next we used the Ste6 assay to determine the effect of a single defined misfolded protein on this mutant. Here we used two distinct Ste6 mutants: L1239X and Q1249X. *rpn4Δ* alone showed sensitivity to both misfolded proteins, as previously reported ([@B21]). However, when combined with the *cho2Δ* mutant, growth was markedly diminished ([Figure 6B](#F6){ref-type="fig"}). Finally, we examined whether loss of Rpn4 could recapitulate Lpl1\'s effects on lipid droplets. Indeed, loss of Rpn4 partially reversed the lipid-droplet phenotype of the *cho2Δ* mutant, again resulting in an increase in the percentage of cells with an intermediate phenotype ([Figure 6, C and D](#F6){ref-type="fig"}). These findings suggest that two separate proteotoxic stress responses---the Rpn4 response and the UPR---are closely linked to phospholipid metabolism and lipid droplet function.

![Rpn4 recapitulates aspects of Lpl1 function. (A) Growth of wild-type, *rpn4Δ*, *cho2Δ*, and *rpn4Δcho2Δ* strains in the presence of canavanine (0.5 µg/ml). Cells were spotted in threefold serial dilutions and cultured at 30°C for 2--4 d. Note that a lower concentration of canavanine was used here than in [Figure 4B](#F4){ref-type="fig"}. (B) Growth of *rpn4Δ* and *rpn4Δcho2Δ* strains expressing galactose-inducible wild-type *STE6* or the misfolded mutant *ste6-L1239X* or *ste6-Q1249X.* Cells were spotted in threefold serial dilutions and cultured for 4 d at 33°C. The *cho2Δ* mutant alone did not show a phenotype under these conditions (unpublished data). (C) Representative images of lipid droplets, as visualized by fluorescence microscopy, for the indicated strains. *cho2Δ* cells show a relative accumulation of cells with a single very large ("supersized") lipid droplet. Similar to *cho2Δlpl1Δ, rpn4Δcho2Δ* cells show a relative accumulation of cells with an intermediate phenotype (i.e., lipid droplets that are smaller but more numerous than those seen in *cho2Δ*). (D) Quantitation of normal, intermediate, and supersized lipid droplets. Six hundred cells were counted (in 100 cell groups) for each strain. Error bars represent SDs. Asterisk, statistically significant by Student\'s *t* test (*p* \< 0.001). Note that all six strains represented in [Figures 5A](#F5){ref-type="fig"} and [6C](#F6){ref-type="fig"} were analyzed as a group. Thus the values for wild-type and *cho2Δ* are the same in both.](716fig6){#F6}

DISCUSSION
==========

Novel aspects **of the Rpn4** proteotoxic stress response
---------------------------------------------------------

Rpn4\'s best-known function is the coordinated regulation of proteasome biosynthesis ([@B20]; [@B38]). Accordingly, Rpn4\'s major known transcriptional targets include the ∼35 subunits of the proteasome, as well as an increasing number of proteasome-associated proteins that may be present in substoichiometric amounts or associate reversibly ([@B20]; [@B19]; Sa-Moura *et al.*, [@B25]; [@B12]). Thus Lpl1 is a quite unusual transcriptional target for Rpn4. Our assignment of Lpl1 as an Rpn4 effector is supported by two prior microarray studies that detected transcriptional induction of *LPL1* in response to different proteotoxic stressors, although no further analysis of Lpl1 was reported ([@B6]; [@B21]).

Our results suggest a broader role for Rpn4 in proteotoxic stress responses than was previously anticipated. Indeed, bioinfomatics analyses have identified potential PACE motifs in the promoters of many nonproteasomal genes ([@B20]; [@B30]). Moreover, transcriptional profiling experiments indicate many more potential Rpn4 targets, possibly numbering in the hundreds ([@B16]). The determination of the full breadth and function of the Rpn4 response remains an important goal for future work and will ultimately require a comprehensive analysis of the function of each Rpn4 effector.

Role of phospholipid metabolism in proteotoxic stress responses
---------------------------------------------------------------

The Rpn4 response and the UPR appear to represent largely distinct pathways. Proteasome subunits, for example, are not direct transcriptional targets of the UPR ([@B33]). Similarly, the dedicated ERAD components controlled by the UPR (e.g., Hrd1, Hrd3, and Ubc7) are not targets of Rpn4. Our work suggests a novel and interesting parallel between the two pathways: each regulates phospholipid metabolism. The UPR stimulates phospholipid synthesis, whereas Rpn4 regulates phospholipid breakdown via Lpl1. The precise role of phospholipid synthesis in the UPR has remained somewhat unclear. An attractive model is that protein misfolding in the ER may be mitigated by expanding the compartment, in effect diluting the concentration of misfolded proteins ([@B26]). Because phospholipids are major constituents of membranes, new phospholipid synthesis may be required for this process. An alternate model, not mutually exclusive, is that remodeling of membranes could alter the folding environment within the ER, providing a better environment for protein folding. This could proceed by altering the physicochemical properties of membranes, for example, by changing the hydrophobicity, length, or degree of unsaturation of membrane phospholipids.

An interesting aspect of Lpl1 is that its role in protein degradation became apparent only after compromising the UPR in the *hac1Δ* mutant. Hac1 regulates many different cellular processes and controls the expression of potentially hundreds of genes ([@B17]; [@B33]). In principle, dysregulation of any of these genes could represent the basis for the *hac1∆lpl1∆* mutant. Our data suggest that Hac1\'s control of phospholipid synthesis is particularly relevant for Lpl1 function. This is supported by the observation that impairing phospholipid synthesis in the *cho2∆lpl1∆* and the *psd1∆lpl1∆* mutants phenocopies the *hac1∆lpl1∆* mutant ([Figure 4, B and C](#F4){ref-type="fig"}). A simple model is that recycling of lipid droplet phospholipids by Lpl1 provides precursor products that can be used in new phospholipid synthesis. In this regard, the lipid droplet, in addition to storing neutral lipids, may also serve as a functional reservoir of phospholipids. Alternatively, and not mutually exclusive, the free fatty acids liberated by Lpl1 ([Figure 1D](#F1){ref-type="fig"}) could be used in another process, such as energy production via beta oxidation or lipid modification of proteins (e.g., myristoylation). Further work is needed to test these models.

Role of Lpl1 in lipid droplet function
--------------------------------------

The lipid droplet is bounded by a phospholipid monolayer. Lpl1 appears to break down these phospholipids ([@B27]), and this loss might be expected to result in smaller lipid droplet particles. By contrast, we see that the accumulation of very large lipid droplets in the *cho2Δ* mutant is partially dependent on Lpl1 ([Figure 5, A and B](#F5){ref-type="fig"}). Similarly, simply overexpressing Lpl1 in a wild-type background resulted in larger lipid droplet size ([@B27]). A key observation in this regard is that the increase in lipid droplet size in the *cho2Δ* mutant is accompanied by a decrease in the number of lipid droplet particles per cell ([Figure 5A](#F5){ref-type="fig"}; [@B5]). Thus a straightforward explanation for the seemingly paradoxical effect of Lpl1 is that lipid droplet catabolism by Lpl1 is accompanied by fusion of the smaller lipid droplet particles, resulting in larger but fewer lipid droplets in the cell. Proteomic analysis indicates that Lpl1 is significantly induced in the *cho2Δ* mutant (see Supplemental Table 3 of [@B32]), further supporting this notion. This also suggests that formation of supersized lipid droplets in the *cho2Δ* mutant may be part of a protective response related to phospholipid deficiency. Indeed, supersized lipid droplets are seen only when *cho2Δ* cells are cultured in synthetic (i.e., minimal) media ([@B5]; unpublished data). They are not seen in rich media, presumably because cells can take up precursor products from the extracellular environment and synthesize phospholipids through the alternate Kennedy pathway ([@B2]).

Why lipid droplet fusion should occur is unclear. The lipid droplet houses large quantities of neutral lipids, and the phospholipid monolayer ensures that this densely hydrophobic core is shielded from the aqueous environment. Lipid droplet fusion thus may be a response to ensure the integrity of the particle as phospholipids become limiting within the monolayer. Modeled as a sphere, the ratio of volume to surface area should increase as the diameter of the lipid droplet increases. How lipid droplet fusion could occur and whether this is a regulated process also remain unclear. At least one report suggests that purified lipid droplets in vitro could fuse without supplementing ATP or cytoplasmic constituents ([@B4]).

Relationships between proteotoxic stress, lipid metabolism, and human disease
-----------------------------------------------------------------------------

The role of protein quality control in human disease is well established, particularly in the family of neurodegenerative diseases that are believed to be caused by the toxic accumulation of misfolded proteins. However, a number of intriguing clinical and basic observations over many years has linked proteotoxic stress responses, particularly the unfolded protein response, to diseases of lipid metabolism, including obesity, insulin resistance, and diabetes ([@B14]; [@B34]). For example, obesity is associated with induction of the unfolded protein response ([@B22]), and weight loss correlates with reduced ER stress ([@B8]). Conversely, mutants deficient in the unfolded protein response develop insulin resistance ([@B22]). These relationships between protein degradation, lipid metabolism, and dyslipidemia remain poorly understood at a molecular level. Lpl1 directly links proteotoxic stress responses to lipid droplet function and thus provides a mechanistic basis for further understanding these complex relationships between protein degradation and lipid metabolism.

MATERIALS AND METHODS
=====================

Strains and plasmids
--------------------

Yeast strains and plasmids are listed in [Tables 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}, respectively. Standard techniques were used for strain constructions and transformations. YPD medium consisted of 1% yeast extract, 2% Bacto-peptone, and 2% dextrose. Synthetic medium consisted of 0.7% Difco Yeast Nitrogen Base supplemented with amino acids, adenine, uracil, and 2% dextrose. Where appropriate, the relevant amino acid or nucleic acid was omitted for plasmid selection. Where appropriate, 2% galactose was used instead of dextrose to induce gene expression.

###### 

Yeast strains.

  Strain    Genotype                                                               Reference
  --------- ---------------------------------------------------------------------- ---------------
  BY4741    *MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0*                                    RG Collection
  *rpn4Δ*   *MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 rpn4::KAN*                          RG Collection
  *lpl1Δ*   *MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 lpl1::KAN*                          RG Collection
  *hac1Δ*   *MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 hac1::KAN*                          RG Collection
  sJH522    *MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 hac1::KAN lpl1::HYG*                This study
  sJH536    *MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0* \[ycPlac33\]                       This study
  sJH537    *MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 lpl1::KAN* \[ycPlac33\]             This study
  sJH538    *MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 hac1::KAN* \[ycPlac33\]             This study
  sJH539    *MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 hac1::KAN lpl1::HYG* \[ycPlac33\]   This study
  sJH540    *MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 hac1::KAN lpl1::HYG* \[pJH197\]     This study
  sJH559    *MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0* \[pSM1763\]                        This study
  sJH560    *MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 lpl1::KAN* \[pSM1763\]              This study
  sJH561    *MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 hac1::KAN* \[pSM1763\]              This study
  sJH562    *MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 hac1::KAN lpl1::HYG* \[pSM1763\]    This study
  sJH571    *MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0* \[pJH146\]                         This study
  sJH572    *MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 lpl1::KAN* \[pJH146\]               This study
  sJH573    *MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 hac1::KAN* \[pJH146\]               This study
  sJH574    *MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 hac1::KAN lpl1::HYG* \[pJH146\]     This study
  sJH630    *MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0* \[pSM1897\]                        This study
  sJH631    *MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0* \[pSM2213\]                        This study
  sJH632    *MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 lpl1::KAN* \[pSM1897\]              This study
  sJH633    *MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 lpl1::KAN* \[pSM2213\]              This study
  sJH634    *MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 hac1::KAN* \[pSM1897\]              This study
  sJH635    *MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 hac1::KAN* \[pSM2213\]              This study
  sJH636    *MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 hac1::KAN lpl1::HYG* \[pSM1897\]    This study
  sJH637    *MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 hac1::KAN lpl1::HYG* \[pSM2213\]    This study
  *cho2Δ*   *MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 cho2::KAN*                          RG Collection
  sJH575    *MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 cho2::KAN lpl1::HYG*                This study
  *dga1Δ*   *MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 dga1::KAN*                          RG Collection
  sJH576    *MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 dga1::KAN lpl1::HYG*                This study
  *psd1Δ*   *MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 psd1::KAN*                          RG Collection
  sJH598    *MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 psd1::KAN lpl1::HYG*                This study
  sJH612    *MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 cho2::KAN rpn4::NAT*                This study
  sJH614    *MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 rpn4::KAN* \[pSM1897\]              This study
  sJH615    *MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 rpn4::KAN* \[pSM2212\]              This study
  sJH616    *MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 rpn4::KAN* \[pSM2213\]              This study
  sJH638    *MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 cho2::KAN rpn4::NAT* \[pSM1897\]    This study
  sJH639    *MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 cho2::KAN rpn4::NAT* \[pSM2212\]    This study
  sJH640    *MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 cho2::KAN rpn4::NAT* \[pSM2213\]    This study

Research Genetics (RG) Collection strains are available from ThermoFisher Scientific.

###### 

Yeast plasmids.

  Plasmid    Details                            Reference
  ---------- ---------------------------------- ------------
  ycPlac33   Empty vector (CEN/URA3)            [@B7]
  pJH197     *LPL1* (in ycPlac33, CEN/URA3)     This study
  pSM1763    *CPY\*-HA* (CEN/URA3)              [@B15]
  pJH146     Δ2-GFP-HA (HIS3)                   [@B18]
  pSM1897    p^GAL1^STE6-GFP (2µ/*URA3)*        [@B21]
  pSM2213    p^GAL1^*ste6-Q1249X* (2µ/*URA3)*   [@B21]
  pSM2212    p^GAL1^*ste6-L1239X* (2µ/*URA3)*   [@B21]

Proteomic analysis
------------------

Proteomic analysis to determine the cellular response to trivalent arsenic was previously performed using a tandem mass tag-based mass spectrometry approach and was described in detail ([@B9]). Data for nearly 4600 proteins were obtained in triplicate at 0, 1, and 4 h after treatment. The data shown here for Lpl1 represent further original analysis of that data set.

RT-PCR
------

RT-PCR was carried out as previously described ([@B10]). *LPL1* was amplified with the primers 5-AATGAGGTCAGAGGAAAATTAGG-3 and 5-TCAATTACTCTTGTGCATCAAG-3. *ACT1* was amplified with the primers 5-CTGGTATGTTCTAGCGCTTG-3 and 5-GATACCTTGGTGTCTTGGTC-3. *HAC1* was amplified with the primers 5-CACTCGTCGTCTGATACG-3 and 5-CATTCAATT­CAAATGAATTCAAACCTG-3. These primers amplify unspliced and spliced *HAC1* species. As a positive control for *HAC1* splicing, cells were treated with tunicamycin at 5 μg/ml for 1 h.

Phenotypic analysis
-------------------

Cells from overnight cultures were standardized by optical density and spotted in threefold serial dilutions onto the indicated plates and incubated at the indicated temperatures.

Degradation assays and immunoblot analysis
------------------------------------------

To analyze total ubiquitin conjugates, whole-cell extracts were prepared from exponential-phase cultures. Cells were normalized by optical density; cell pellets were resuspended in 1× Laemmli loading buffer (LLB) and boiled for 5 min. For all other immunoblots, extracts were prepared by a lithium acetate/sodium hydroxide method as follows. Exponential-phase cultures were normalized by optical density, treated with 2 M lithium acetate on ice for 5 min, and then treated with 0.4 M sodium hydroxide on ice for 5 min. Cell pellets were resuspended in 1× LLB and boiled for 5 min. Analysis was by standard SDS--PAGE followed by immunoblotting. For cycloheximide chase analyses, cycloheximide (100 µg/ml) was added at time 0 to inhibit protein synthesis, and extracts were prepared as described at the indicated time points. Note that the experiments of [Figure 3, A--C and E](#F3){ref-type="fig"}, were carried out at 37°C. Where indicated, the unfolded protein response was induced by treating cells with tunicamycin at 5 μg/ml for 1 h.

The following antibodies were used: anti-ubiquitin (SC-8017; Santa Cruz Biotechnology), anti-Pgk1 (459250; Invitrogen), anti--HA-peroxidase (12013819001; Roche), anti-actin (MA511866; ThermoFisher), anti--phospho-eIF2α (9721S; Cell Signaling Technology), and anti-Kar2 (sc-33630; Santa Cruz Biotechnology).

Lipid droplet fluorescence microscopy
-------------------------------------

Logarithmically growing cells were cultured in minimal medium and shifted to 37°C for 1 h before harvesting. Cells were fixed with 2% formaldehyde and incubated with 0.5 µg/ml BODIPY 493/503 (ThermoFisher Scientific; [@B27]). Lipid droplets were visualized by fluorescence microscopy using an Olympus BX51 microscope outfitted with a 100× oil immersion objective and the appropriate filters.

To quantify lipid droplets, six groups of 100 cells each were counted sequentially over multiple days for each strain. The normal pattern consisted of 5--10 small dispersed lipid droplets per cell. The "supersized" pattern consisted of a single dominant lipid droplet, typically with no other visible lipid droplets or 1 or 2 small lipid droplets. The intermediate pattern consisted of 2--5 lipid droplets that were intermediate in size between normal and supersized. Lipid droplet distributions were analyzed by SD and two-tailed Student\'s *t* test.
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CPY

:   carboxypeptidase Y

ER

:   endoplasmic reticulum

ERAD

:   ER-associated degradation

LLB

:   Laemmli loading buffer

PACE

:   proteasome-associated control element

RT-PCR

:   reverse transcription PCR

UPR

:   unfolded protein response.
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